William Berg, MD
Cardiovascular Disease · Indianapolis, INNPI 1225009749
Payments from drug & device makers
Across 104 payments — averaging $180.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- EKOS Corporation$4K
- Abbott$865
- Bard Peripheral Vascular, Inc.$664
- Medtronic$539
- Biotronik Inc.$277
- plus $1K from 18 others
What the payments were for
- Consulting fees$7,00049%
- Travel & lodging$1,96814%
- Food & beverage$5,26337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 33 | $11,804 |
| EKOS Corporation | 1 | $3,500 |
| Abbott | 18 | $865 |
| Bard Peripheral Vascular, Inc. | 7 | $664 |
| Medtronic(2 entities) | 9 | $539 |
| Biotronik Inc. | 5 | $277 |
| Shockwave Medical, Inc | 2 | $238 |
| Inari Medical, Inc. | 3 | $138 |
| Philips North America LLC | 3 | $132 |
| Edwards Lifesciences | 4 | $118 |
| Reflow Medical Inc | 1 | $108 |
| Angiodynamics, Inc. | 1 | $82 |
| Novartis | 4 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $24 |
| Teleflex LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Cardiva Medical, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Terumo Medical Corporation | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Biosense Webster, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL HEART$4,000
- GENERAL VASCULAR ACCESS$3,000
- GENERAL - THERAPIES$1,963
- GENERAL VASCULAR INTERVENTION$520
- LATITUDE$207
- LUTONIX$159
- Supera peripheral stent system$154
- ONYX FRONTIER$144
- Vascular Lithotripsy$130
- FlowTriever$115
- ClotTriever$115
- INTERSTIM$115
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$109
- Emboshield NAV6 system$103
How this compares
$18,731 in reported general payments places this provider in the 75th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $199,534 |
| Repatha SureclickEvolocumab | 61 | $74,687 |
| EntrestoSacubitril/Valsartan | 64 | $73,404 |
| XareltoRivaroxaban | 26 | $39,748 |
| JardianceEmpagliflozin | 18 | $29,041 |
| BrilintaTicagrelor | 26 | $21,929 |
| Praluent PenAlirocumab | 16 | $19,322 |
| Ezetimibe | 188 | $4,453 |
| Atorvastatin Calcium | 406 | $4,135 |
| Metoprolol Succinate | 233 | $2,946 |
| ClopidogrelClopidogrel Bisulfate | 249 | $2,085 |
| Amiodarone Hcl | 16 | $1,641 |
| Carvedilol | 197 | $1,614 |
| Losartan Potassium | 170 | $1,550 |
| Ranolazine ErRanolazine | 23 | $1,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $56 | $73,40464 claims |
| Boehringer IngelheimJardiance | $13 | $29,04118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Vijay RaoIndianapolis$706K
- Roopa RaoIndianapolis$481K
- Julie ClaryIndianapolis$475K
- James TrippiIndianapolis$449K
- John MillerIndianapolis$354K
- Richard KovacsIndianapolis$338K
- David KovacichIndianapolis$327K
- Jose Emanuel FinetIndianapolis$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.